Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer
Immune adjuvants are immune modulators that have been developed in the context of infectious vaccinations. There is currently a growing interest in immune adjuvants due to the development of immunotherapy against cancers. Immune adjuvant mechanisms of action are focused on the initiation and amplifi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
China Anti-Cancer Association
2023-12-01
|
| Series: | Cancer Biology & Medicine |
| Subjects: | |
| Online Access: | https://www.cancerbiomed.org/content/20/12/1021 |
| _version_ | 1827357111874486272 |
|---|---|
| author | Jean-François Rossi Patrick Frayssinet Maksim Matciyak Nikolai Tupitsyn |
| author_facet | Jean-François Rossi Patrick Frayssinet Maksim Matciyak Nikolai Tupitsyn |
| author_sort | Jean-François Rossi |
| collection | DOAJ |
| description | Immune adjuvants are immune modulators that have been developed in the context of infectious vaccinations. There is currently a growing interest in immune adjuvants due to the development of immunotherapy against cancers. Immune adjuvant mechanisms of action are focused on the initiation and amplification of the inflammatory response leading to the innate immune response, followed by the adaptive immune response. The main activity lies in the support of antigen presentation and the maturation and functions of dendritic cells. Most immune adjuvants are associated with a vaccine or incorporated into the new generation of mRNA vaccines. Few immune adjuvants are used as drugs. Hydroxyapatite (HA) ceramics and azoximer bromide (AZB) are overlooked molecules that were used in early clinical trials, which demonstrated clinical efficacy and excellent tolerance profiles. HA combined in an autologous vaccine was previously developed in the veterinary field for use in canine spontaneous lymphomas. AZB, an original immune modulator derived from a class of heterochain aliphatic polyamines that is licensed in Russia, the Commonwealth of Independent States, and Slovakia for infectious and inflammatory diseases, is and now being developed for use in cancer with promising results. These two immune adjuvants can be combined in various immunotherapy strategies. |
| first_indexed | 2024-03-08T05:20:45Z |
| format | Article |
| id | doaj.art-35700de565c0488a961461b5d42dcf8c |
| institution | Directory Open Access Journal |
| issn | 2095-3941 |
| language | English |
| last_indexed | 2024-03-08T05:20:45Z |
| publishDate | 2023-12-01 |
| publisher | China Anti-Cancer Association |
| record_format | Article |
| series | Cancer Biology & Medicine |
| spelling | doaj.art-35700de565c0488a961461b5d42dcf8c2024-02-06T12:47:11ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412023-12-0120121021103410.20892/j.issn.2095-3941.2023.0222Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancerJean-François Rossi0Patrick Frayssinet1Maksim Matciyak2Nikolai Tupitsyn3Institut du Cancer Avignon-Provence, Sainte Catherine – Department of Hematology-Biotherapy, Avignon 84918, FranceHASTIM Inc., Rue de Caulet, Toulouse 31300, FrancePetrovax NPO Pharm, Moscow 123112, RussiaLaboratory of Immunology of Hematopoiesis, N.N. Blokhin Cancer Research Center (RCRC), Moscow 123112, RussiaImmune adjuvants are immune modulators that have been developed in the context of infectious vaccinations. There is currently a growing interest in immune adjuvants due to the development of immunotherapy against cancers. Immune adjuvant mechanisms of action are focused on the initiation and amplification of the inflammatory response leading to the innate immune response, followed by the adaptive immune response. The main activity lies in the support of antigen presentation and the maturation and functions of dendritic cells. Most immune adjuvants are associated with a vaccine or incorporated into the new generation of mRNA vaccines. Few immune adjuvants are used as drugs. Hydroxyapatite (HA) ceramics and azoximer bromide (AZB) are overlooked molecules that were used in early clinical trials, which demonstrated clinical efficacy and excellent tolerance profiles. HA combined in an autologous vaccine was previously developed in the veterinary field for use in canine spontaneous lymphomas. AZB, an original immune modulator derived from a class of heterochain aliphatic polyamines that is licensed in Russia, the Commonwealth of Independent States, and Slovakia for infectious and inflammatory diseases, is and now being developed for use in cancer with promising results. These two immune adjuvants can be combined in various immunotherapy strategies.https://www.cancerbiomed.org/content/20/12/1021immune adjuvantscancerazoximer bromidehydroxyapatitetoll receptor agonistsimmunotherapy |
| spellingShingle | Jean-François Rossi Patrick Frayssinet Maksim Matciyak Nikolai Tupitsyn Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer Cancer Biology & Medicine immune adjuvants cancer azoximer bromide hydroxyapatite toll receptor agonists immunotherapy |
| title | Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer |
| title_full | Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer |
| title_fullStr | Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer |
| title_full_unstemmed | Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer |
| title_short | Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer |
| title_sort | azoximer bromide and hydroxyapatite promising immune adjuvants in cancer |
| topic | immune adjuvants cancer azoximer bromide hydroxyapatite toll receptor agonists immunotherapy |
| url | https://www.cancerbiomed.org/content/20/12/1021 |
| work_keys_str_mv | AT jeanfrancoisrossi azoximerbromideandhydroxyapatitepromisingimmuneadjuvantsincancer AT patrickfrayssinet azoximerbromideandhydroxyapatitepromisingimmuneadjuvantsincancer AT maksimmatciyak azoximerbromideandhydroxyapatitepromisingimmuneadjuvantsincancer AT nikolaitupitsyn azoximerbromideandhydroxyapatitepromisingimmuneadjuvantsincancer |